[The concomitant effects of SM-4300 with some antibiotics on severe bacterial and/or fungal infections in surgery].
SM-4300, a newly developed human immunoglobulin preparation, has been studied for the safety and effectiveness/efficacy in the 16 patients with severe bacterial and/or fungal infections which are resistant to antibiotic therapy. Clinical effect of 16 cases were excellent 1 case, good 4, fair 4, poor 4 and unknown 3. The efficacy rate was 38.5% and the efficacy rate including fair was 69.2%. No remarkable adverse reaction due to administration of SM-4300 were observed.